Chronic myeloid leukemia (CML) is sometimes mentioned as the disease of “firsts”. 1) It is
the first disease where the term “leukemia” was used. 2) It is the first neoplastic disorder …

The past three decades have witnessed chronic myeloid leukemia (CML), a clonal disease
that results from an acquired genetic change in a single pluripotential hemopoietic stem cell …

Leukemia is a cancer of marrow and blood, which is a clonal myeloproliferative disease,
characterized by the presence of oncogenic Philadelphia chromosome, formed by a …

Patients with splenomegaly and abnormally high leukocyte counts were first recognized in
France, Germany, and Scotland in the 1840s. The only well-documented therapy in the 19th …

The treatment of patients with chronic myeloid leukemia (CML) continues to evolve rapidly
as we gain better insights into the best monitoring strategies and as there is experience with …

The advent of tyrosine kinase inhibitors (TKIs) has drastically changed the treatment
outcome of chronic myeloid leukemia (CML). Imatinib was the first TKI approved, and has …

The clinical outcome for patients with chronic myelogenous leukemia (CML) has changed
dramatically in the past 15 years. This has been due to the development of tyrosine kinase …

Purpose of Review A large number of chronic myeloid leukemia (CML) patients receiving
tyrosine kinase inhibitors (TKIs) can now enjoy a deep molecular control of the disease and …

Purpose: The BCR-ABL tyrosine kinase inhibitor imatinib has dramatically improved the
prognosis for most patients with chronic myeloid leukemia (CML). Efforts to optimize therapy …

The biology of chronic myeloid leukemia (CML) has enabled pioneering studies with
targeted therapies. BCR-ABL inhibition with imatinib results in high levels of efficacy in …